Dupuis S, Dani V, Fatfouta I, Staccini P, Delotte J
Service de gynécologie-obstétrique, université Côte d'Azur, affiliation centre hospitalier universitaire de Nice, Archet 2, 151, route Saint-Antoine de Ginestière, 06202 Nice cedex 3, France.
Institut de Biologie Valrose UMR7277, université Côte d'Azur, 06000 Nice, France.
Gynecol Obstet Fertil Senol. 2019 Oct;47(10):739-746. doi: 10.1016/j.gofs.2019.07.008. Epub 2019 Jul 20.
The objective of our study is to evaluate the impact of luteal phase support by hCG in intrauterine inseminations preceded by ovarian gonadotropin stimulation.
A retrospective study was conducted at the CHU of Nice between March 1, 2016 and October 31, 2017. During this period, 300 intrauterine inseminations were included in data analysis. Ovarian stimulation was performed by gonadotropins and a GnRH antagonist was added, if needed. Following a modification of standard operative procedure in the department, patients who performed an intrauterine insemination from December 1, 2016 received luteal phase support with two injections of hCG 1500 IU, performed at three days of interval. Pregnancy and ovarian hyperstimulation syndrome were the primary and secondary study endpoints, respectively.
Out of 300 inseminations included in the analysis, 144 were performed with luteal phase support and 156 without support. No statistically significant difference in pregnancy rate was observed between these two groups (19.4% of pregnancy in the luteal phase support group and 15.38% in the group without luteal phase support, P=0.353). No ovarian hyperstimulation syndrome occurred over the course of the study.
Our study shows a slight improvement of pregnancy rate in the group subjected to luteal phase support by hCG after intrauterine insemination, but the benefit was not significant. A randomised prospective study based on a large cohort could help to assess the effect of luteal phase support during intrauterine inseminations.
本研究的目的是评估在卵巢促性腺激素刺激后的宫内人工授精中，人绒毛膜促性腺激素（hCG）黄体期支持的影响。
于2016年3月1日至2017年10月31日在尼斯大学医疗中心进行了一项回顾性研究。在此期间，300例宫内人工授精纳入数据分析。采用促性腺激素进行卵巢刺激，必要时加用GnRH拮抗剂。自2016年12月1日起，根据科室标准手术程序的修改，接受宫内人工授精的患者接受两次间隔3天的1500IU hCG注射进行黄体期支持。妊娠和卵巢过度刺激综合征分别为主要和次要研究终点。
在纳入分析的300例人工授精中，144例接受黄体期支持，156例未接受支持。两组妊娠率无统计学显著差异（黄体期支持组妊娠率为19.4%，无黄体期支持组为15.38%，P = 0.353）。研究过程中未发生卵巢过度刺激综合征。
我们的研究表明，宫内人工授精后接受hCG黄体期支持的组妊娠率略有提高，但益处不显著。基于大样本队列的随机前瞻性研究可能有助于评估宫内人工授精期间黄体期支持的效果。
